Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

470

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2030

Conditions

Gastric Cancer Stage

Interventions

DRUG

Tislelizumab

Received tislelizumab combined with investigator's choice of chemotherapy

DRUG

SOX or CAPOX regimen

chemotherapy (SOX or CAPOX regimen)

Trial Locations (1)

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou

All Listed Sponsors

collaborator

Sichuan Cancer Hospital and Research Institute

OTHER

collaborator

Liaoning Cancer Hospital & Institute

OTHER

lead

Xiangdong Cheng

OTHER